Low-dose ATGAM treatment sufficiently reduces total T-cell counts and remains clinically effective in prophylactic and anti-rejection protocols.
Department of Vascular and Renal Diseases, Lund University, University Hospital, Malmö, Sweden.
H
H
Ekberg
R
R
Källén
H
H
Schatz
N H
NH
Persson
D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D002985:Clinical Protocols; D016572:Cyclosporine / Q000008:administration & dosage; D006084:Graft Rejection / Q000517:prevention & control* / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D018655:Lymphocyte Count; D013601:T-Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum; D016572:Cyclosporine